Docetaxel

Name: Docetaxel
Brand: Selleck Chemicals
SKU: S1148
Rating: 5 (85 reviews)

For research use only.

Catalog No.S1148 Synonyms: RP56976, NSC 628503

85 publications

CAS No. 114977-28-5

Docetaxel (RP56976, NSC 628503), an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.

Selleck's Docetaxel has been cited by 85 publications

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2018, 174(5):1200-1215

PubMed: 30100187 ( click the link to review the publication )

Nat Commun, 2020, 10;11(1):2935

PubMed: 32523045 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-1168-9

PubMed: 31992853 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-01091-1

PubMed: 33024272 ( click the link to review the publication )

Cells, 2020, 9(1)

PubMed: 31947623 ( click the link to review the publication )

Cells, 2020, 9(6):E1474

PubMed: 32560232 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(1):39-51

PubMed: 31582531 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(2):364-374

PubMed: 31712394 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(8):2649-2676

PubMed: 32905466 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(1):249-262

PubMed: 32064165 ( click the link to review the publication )

Oncogenesis, 2020, 7;9(5):45

PubMed: 32382014 ( click the link to review the publication )

Front Oncol, 2020, 1.4125

PubMed: 31998647 ( click the link to review the publication )

Int J Biol Sci, 2020, 16(7):1121-1134

PubMed: 32174789 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Exp Cell Res, 2020, 10.1016/j.yexcr.2020.111981

PubMed: 32234375 ( click the link to review the publication )

Toxicol In Vitro, 2020, 104928

PubMed: 32622998 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Pharmaceutics, 2020, 30;12(5) pii: E413

PubMed: 32366029 ( click the link to review the publication )

Sci Rep, 2020, 10(1):13124

PubMed: 32753665 ( click the link to review the publication )

Cell Death Dis, 2020, 11(7):577

PubMed: 32709853 ( click the link to review the publication )

Cancer Lett, 2020, 470:95-105

PubMed: 31644929 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-0206

PubMed: 31113844 ( click the link to review the publication )
Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Theranostics, 2019, 9(19):5464-5477

PubMed: 31534497 ( click the link to review the publication )

Cancer Res, 2019, canres.0656.2019

PubMed: 31694904 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2317-2330

PubMed: 31461649 ( click the link to review the publication )

Cell Rep, 2019, 28(13):3367-3380

PubMed: 31553907 ( click the link to review the publication )

Cell Death Differ, 2019, 10.1038/s41418-019-0473-8

PubMed: 31857702 ( click the link to review the publication )

Int J Cancer, 2019, 145(7):1970-1981

PubMed: 30807643 ( click the link to review the publication )

Cancers (Basel), 2019, 11(4)

PubMed: 31018595 ( click the link to review the publication )

Cell Death Discov, 2019, 0.30486111111

PubMed: 31583122 ( click the link to review the publication )

Cell Death Dis, 2019, 10(9):660

PubMed: 31506430 ( click the link to review the publication )

Arch Toxicol, 2019, 93(4):953-964

PubMed: 30863990 ( click the link to review the publication )

Cells, 2019, 9(1)

PubMed: 31877673 ( click the link to review the publication )

J Virol, 2019, 93(4)

PubMed: 30487274 ( click the link to review the publication )

Sci Rep, 2019, 9(1):16647

PubMed: 31719636 ( click the link to review the publication )

Mol Cell Endocrinol, 2019, 498:110585

PubMed: 31536779 ( click the link to review the publication )

Clin Exp Metastasis, 2019, 36(2):97-108

PubMed: 30810874 ( click the link to review the publication )

Prostate, 2019, 79(11):1304-1315

PubMed: 31212367 ( click the link to review the publication )

Prostate, 2019, 79(9):1018-1031

PubMed: 31018021 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2019, 145(3):551-559

PubMed: 30474758 ( click the link to review the publication )

Cancer Med, 2019, 10.1002/cam4.2764

PubMed: 31823522 ( click the link to review the publication )

Onco Targets Ther, 2019, 12:9899-9913

PubMed: 31819487 ( click the link to review the publication )

J Org Chem, 2019, 10.1021/acs.joc.9b02414

PubMed: 31858795 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(24):6421-6432

PubMed: 30087142 ( click the link to review the publication )

Cell Death Dis, 2018,

PubMed: 29752436 ( click the link to review the publication )
Mol Cancer Ther, 2018, 17(9):2024-2033

PubMed: 29959202 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14672

PubMed: 30279484 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:6695-6703

PubMed: 30584364 ( click the link to review the publication )

Biomed Pharmacother, 2018, 99:445-450

PubMed: 29665645 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Oncol Rep, 2018, 39(4):1901-1909

PubMed: 29393407 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2018, 81(2):255-267

PubMed: 29189915 ( click the link to review the publication )

Gene, 2018, 658:152-158

PubMed: 29518547 ( click the link to review the publication )

Int Urol Nephrol, 2018, 50(4):675-686

PubMed: 29460131 ( click the link to review the publication )

Ann Surg Treat Res, 2018, 95(5):240-248

PubMed: 30402442 ( click the link to review the publication )

Oncotarget, 2018,

PubMed: 29560108 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(18):E3729-E3738

PubMed: 28416665 ( click the link to review the publication )

Cancer Res, 2017, 77(12):3268-3279

PubMed: 28400477 ( click the link to review the publication )

Oncogene, 2017, 36(14):1991-2001

PubMed: 27721412 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2552-2562

PubMed: 28847989 ( click the link to review the publication )

Mol Cancer Ther, 2017, 77(22):6282-6298

PubMed: 28424227 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(6):660-669

PubMed: 28209757 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(1):20-34

PubMed: 28760737 ( click the link to review the publication )

Breast Cancer Res Treat, 2017, 165(3):531-543

PubMed: 28695300 ( click the link to review the publication )

Oncol Lett, 2017, 14(4):4349-4354

PubMed: 28959367 ( click the link to review the publication )

Oncotarget, 2017, 9(9):8206-8222

PubMed: 29492189 ( click the link to review the publication )

Oncotarget, 2017, 9(4):4886-4896

PubMed: 29435149 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(10):2302-2313

PubMed: 27474148 ( click the link to review the publication )

Prostate Cancer Prostatic Dis, 2016, 19(4):349-357

PubMed: 27349498 ( click the link to review the publication )
Int J Cancer, 2015, 136(9):2065-77

PubMed: ( click the link to review the publication )

Breast Cancer Res, 2015, 17:59

PubMed: 25902869 ( click the link to review the publication )

Biochem Pharmacol, 2015, 10.1016/j.bcp.2015.05.005

PubMed: ( click the link to review the publication )

PLoS ONE, 2015,

PubMed: 25969993 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123901

PubMed: 25875914 ( click the link to review the publication )

Oncotarget, 2015, 6(29):27923-37

PubMed: 26314846 ( click the link to review the publication )

Oncotarget, 2015, 6(27):23358-71

PubMed: 26160840 ( click the link to review the publication )

Oncotarget, 2015, 6(1):56-70

PubMed: 25474141 ( click the link to review the publication )

Oncogenesis, 2014, 3:e100

PubMed: 24752235 ( click the link to review the publication )

Mol Pharm, 2014, 11(7):2040-50

PubMed: 24779589 ( click the link to review the publication )

J Cell Mol Med, 2014, 18(5):811-23

PubMed: 24628949 ( click the link to review the publication )

J Nucl Med, 2013, 54(6):913-21

PubMed: 23564760 ( click the link to review the publication )

J Transl Med, 2013, 11:204

PubMed: 24004449 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description

Docetaxel (RP56976, NSC 628503), an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.

Targets

Microtubules ^[1]
(Cell-free assay)

In vitro

Docetaxel is a cytotoxic agent, especially for proliferating cells, which is related to its ability to promote the formation of microtubule bundles and induce sustained mitotic arrest, followed by apoptosis of mitotically arrested cells or permanent mitotic block. Docetaxel suppresses microtubule dynamic instability as well as tread-milling, resulting in the failure of chromosomes to segregate to the daughter cells, which in turn triggers premature exit from mitosis rather than a block at this phase of the cell cycle. ^[2] Docetaxel inhibits the clonogenic survival of Human cancer cell Hs746T (stomach), AGS (stomach), HeLa (cervix), CaSki (cervix), BxPC3 (pancreas), Capan-1 (pancreas) with IC50 of 1 nM, 1 nM, 0.3 nM, 0.3 nM, 0.3 nM and 0.3 nM respectively. ^[4] Docetaxel inhibits endothelial cell migration that does not affects microtubule gross morphology or inhibit cell proliferation, although they does produce more subtle effects on microtubule dynamics. Docetaxel inhibits HUVEC migration with an observed IC50 of 1 pM. HUVEC chemotaxis stimulated by either of two angiogenic factors, thymidine phosphorylase or VEGF, is inhibited by Docetaxel with IC 50 of 10 pM and is ablated at 1 nM. ^[7] Docetaxel induces human monocytes, but not RAW 264.7 murine macrophages, Prostaglandin H Synthase-2m (PGHS-2) expression. ^[8]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
HSC-3	NH30TWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4Xl[WlEPTB;MD6wNFAyOzJizszN	NF3ofo5USU6JRWK=
5637	M3LCVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2XFd2lEPTB;MD6wNFAyPDNizszN	NGnWOWZUSU6JRWK=
HT-144	M1zpcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2XoR2lEPTB;MD6wNFAyPTdizszN	MYXTRW5ITVJ?
NCI-H292	NVLsSGp2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nZXWlEPTB;MD6wNFAyPTlizszN	NV\SPWVIW0GQR1XS
HCE-T	NVv0N\|h[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LBOGlEPTB;MD6wNFAyPjJizszN	M1vyV3NCVkeHUh?=
ESS-1	NWXwSJdHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTBwMECwNVc6KM7:TR?=	NYnCWXZLW0GQR1XS
D-566MG	Mm\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIPPS45KSzVyPUCuNFAxOTh{IN88US=>	NXnmNYN5W0GQR1XS
CAL-62	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYP4W\|k{UUN3ME2wMlAxODF6NTFOwG0>	MkXuV2FPT0WU
GT3TKB	NYPVXGllT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTBwMECwNlMzKM7:TR?=	MoLVV2FPT0WU
HSC-4	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{T0bmlEPTB;MD6wNFAzOzlizszN	MUTTRW5ITVJ?
KOSC-2	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LSNGlEPTB;MD6wNFAzPTVizszN	Mlm0V2FPT0WU
NB14	NFnvTnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTBwMECwNlYh\|ryP	NWPyelhlW0GQR1XS
ES8	MofSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLsTWM2OD1yLkCwNFI3KM7:TR?=	Mnr6V2FPT0WU
BFTC-905	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1:yWGlEPTB;MD6wNFAzPjhizszN	M4PNXXNCVkeHUh?=
A498	NEXBSFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTBwMECwNlc5KM7:TR?=	M4C4fHNCVkeHUh?=
HO-1-N-1	M3;oO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHHZWY9KSzVyPUCuNFAxOjhzIN88US=>	NIX5VGVUSU6JRWK=
SF539	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4r2UGlEPTB;MD6wNFA{ODJizszN	MnLVV2FPT0WU
HuO-3N1	M2n0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3kS25mUUN3ME2wMlAxODNyMjFOwG0>	M1LFRXNCVkeHUh?=
NCI-H510A	NFiyeVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTBwMECwN\|M3KM7:TR?=	M{HUNXNCVkeHUh?=
CAL-27	NYnuXFJLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVTDWIJKUUN3ME2wMlAxODN\|OTFOwG0>	NWXDdlV2W0GQR1XS
TE-8	NGjRNWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PCXWlEPTB;MD6wNFA{PjZizszN	NVPW[\|hqW0GQR1XS
VA-ES-BJ	M1\aOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHKxcldKSzVyPUCuNFAxOzd3IN88US=>	MnrzV2FPT0WU
RH-1	MoLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXTZUZZ[UUN3ME2wMlAxODN6NjFOwG0>	MoPEV2FPT0WU
COLO-800	NYPmZXExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjlTWM2OD1yLkCwNFM5QCEQvF2=	M{HTT3NCVkeHUh?=
ES7	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlj2TWM2OD1yLkCwNFM5QSEQvF2=	MVHTRW5ITVJ?
GAMG	NU\UXHBiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2f3c2lEPTB;MD6wNFA1OTZizszN	MmXkV2FPT0WU
Ca9-22	NFPocmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTtUZZsUUN3ME2wMlAxODR{MzFOwG0>	M{PIVXNCVkeHUh?=
SBC-1	NXXUOolFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPlTWM2OD1yLkCwNFQ{KM7:TR?=	NEjSSItUSU6JRWK=
RPMI-7951	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHuz[WNKSzVyPUCuNFAxPDR6IN88US=>	NFToVWhUSU6JRWK=
SW1710	NIP3UndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUi0cXJ1UUN3ME2wMlAxODR4NjFOwG0>	NHe5Z4dUSU6JRWK=
HGC-27	NXfYb5JCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\iTWM2OD1yLkCwNFQ4OSEQvF2=	MljLV2FPT0WU
MC-IXC	NWfKNlk5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF33b\|ZKSzVyPUCuNFAxPDd7IN88US=>	NVO2RZpOW0GQR1XS
FTC-133	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFvYO\|RKSzVyPUCuNFAxPDh7IN88US=>	M{PyTnNCVkeHUh?=
HT-1080	NWrtdJd1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mon6TWM2OD1yLkCwNFUxOSEQvF2=	NVP6foR{W0GQR1XS
NMC-G1	MnvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHwc2VKSzVyPUCuNFAxPTF5IN88US=>	NF3uZlNUSU6JRWK=
GI-1	MmPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTBwMECwOVI5KM7:TR?=	M4fqSXNCVkeHUh?=
CGTH-W-1	NEjuZpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{G1[2lEPTB;MD6wNFA2PDJizszN	NWriZldwW0GQR1XS
A2058	NFjKW3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PtPWlEPTB;MD6wNFA2PDRizszN	MlzuV2FPT0WU
ETK-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHGyU4tKSzVyPUCuNFAxPTV6IN88US=>	NHvtUYRUSU6JRWK=
NEC8	MmDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmnaTWM2OD1yLkCwNFU3OSEQvF2=	NFjGSmtUSU6JRWK=
TE-11	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHz3bJBKSzVyPUCuNFAxPTZ7IN88US=>	MnjGV2FPT0WU
NCI-H720	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4WyRmlEPTB;MD6wNFA2QCEQvF2=	NYrXOoxWW0GQR1XS
PSN1	NXnSe5UyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnyTWM2OD1yLkCwNFU5OSEQvF2=	MV\TRW5ITVJ?
SW780	NWi3Z5BVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTBwMECwOVg4KM7:TR?=	NFTyVm1USU6JRWK=
8-MG-BA	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTQ[lR3UUN3ME2wMlAxODV6OTFOwG0>	MVXTRW5ITVJ?
EC-GI-10	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH;i[JlKSzVyPUCuNFAxPTl{IN88US=>	Mk\zV2FPT0WU
SJSA-1	NIT1WHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPXTWM2OD1yLkCwNFYyPSEQvF2=	NEPqU2ZUSU6JRWK=
639-V	M1Sx[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXe2XHZHUUN3ME2wMlAxODZ2NzFOwG0>	MV7TRW5ITVJ?
PFSK-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTBwMECwOlU4KM7:TR?=	MYfTRW5ITVJ?
DMS-273	NVTrXlg5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH\6fpRKSzVyPUCuNFAxPjd2IN88US=>	NXG0fVg3W0GQR1XS
TE-9	MlXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlTJTWM2OD1yLkCwNFY4PiEQvF2=	MV7TRW5ITVJ?
SCC-25	MkS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTBwMECwOlgh\|ryP	NE\0fmNUSU6JRWK=
PA-1	Mn7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jU[2lEPTB;MD6wNFA3QDdizszN	M1uzUnNCVkeHUh?=
MHH-ES-1	NU[zflN1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHyTWM2OD1yLkCwNFch\|ryP	MnH5V2FPT0WU
Daoy	MkjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTBwMECwO{DPxE1?	MVXTRW5ITVJ?
G-402	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTBwMECwO\|A3KM7:TR?=	MV\TRW5ITVJ?
YKG-1	M4XyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{TvT2lEPTB;MD6wNFA4ODdizszN	Ml63V2FPT0WU
Ca-Ski	NF3JT5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDVcIdUUUN3ME2wMlAxODd{ODFOwG0>	NGnoT5hUSU6JRWK=
CHP-212	MnO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGP1bHZKSzVyPUCuNFAxPzNizszN	NFrxZ5lUSU6JRWK=
SCC-4	M3P0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\tdHhKSzVyPUCuNFAxPzN7IN88US=>	MYnTRW5ITVJ?
EW-3	NF;oXW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vMZmlEPTB;MD6wNFA4PDVizszN	NEjCW3BUSU6JRWK=
P12-ICHIKAWA	NHG0OVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnjUHVKSzVyPUCuNFAxPzR3IN88US=>	NEfVZmJUSU6JRWK=
HSC-2	M{PNZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoDsTWM2OD1yLkCwNFc2PSEQvF2=	M2XhRnNCVkeHUh?=
HN	NUnveZQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nsXWlEPTB;MD6wNFA4PThizszN	NXvvU4E3W0GQR1XS
LXF-289	NVrJ[JpOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2HNNWlEPTB;MD6wNFA4PThizszN	NXvSbYdXW0GQR1XS
ES1	MkTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGO5fo1KSzVyPUCuNFAxPzdizszN	MWXTRW5ITVJ?
NTERA-S-cl-D1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPxTWM2OD1yLkCwNFc4OyEQvF2=	M2TROnNCVkeHUh?=
K5	MlnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1uwVmlEPTB;MD6wNFA4PzhizszN	M1K1Z3NCVkeHUh?=
HOS	NEXKV5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\s[mlEPTB;MD6wNFA4QDJizszN	MnLlV2FPT0WU
YH-13	NUf0NFVvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LsXGlEPTB;MD6wNFA4QTFizszN	NFHzOoJUSU6JRWK=
SW954	MkjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnrNTWM2OD1yLkCwNFgzOyEQvF2=	MYfTRW5ITVJ?
KYSE-510	NHHtR\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fLU2lEPTB;MD6wNFA5PCEQvF2=	MUPTRW5ITVJ?
8505C	NYK5[lV{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXXnZ\|RyUUN3ME2wMlAxODh3NDFOwG0>	M{DRXHNCVkeHUh?=
A549	M{fHcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml3KTWM2OD1yLkCwNFg5OiEQvF2=	M3zaOXNCVkeHUh?=
Detroit562	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWrmepdwUUN3ME2wMlAxODlyMjFOwG0>	MoL6V2FPT0WU
ES5	NYLFclN{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX3JR\|UxRTBwMECwPVEh\|ryP	NEfFe\|VUSU6JRWK=
KYSE-140	NYTWXVBQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;wTmlEPTB;MD6wNFA6OzNizszN	NEixUJhUSU6JRWK=
GMS-10	M17z[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3mTWM2OD1yLkCwNFk1OSEQvF2=	M3nRS3NCVkeHUh?=
D-263MG	MmrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7RVJduUUN3ME2wMlAxODl2NzFOwG0>	MlnBV2FPT0WU
BCPAP	M1LH[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjCTWM2OD1yLkCwNFk1PyEQvF2=	MnryV2FPT0WU
CHL-1	NYLoPVRQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2XMfWlEPTB;MD6wNFA6PThizszN	Mo[3V2FPT0WU
RKO	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTBwMECwPVg6KM7:TR?=	M1HDfHNCVkeHUh?=
SW48	M12wUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTBwMECxNFEh\|ryP	MlPhV2FPT0WU
BPH-1	NULxe3pNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXRTJRKSzVyPUCuNFAyODJizszN	MoLMV2FPT0WU
EFO-27	M3H3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4HxdWlEPTB;MD6wNFExOiEQvF2=	M4TrRnNCVkeHUh?=
CAL-33	NET0NndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHTFOotKSzVyPUCuNFAyODRizszN	NX7KN4dqW0GQR1XS
NCI-H1792	M4jjUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF[zcnZKSzVyPUCuNFAyODRizszN	MVjTRW5ITVJ?
BB30-HNC	MmDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGLBOopKSzVyPUCuNFAyODVizszN	NUnLXII2W0GQR1XS
VM-CUB-1	NIL2WlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVj2eY1GUUN3ME2wMlAxOTB3IN88US=>	M{nzWnNCVkeHUh?=
TE-5	M1HMXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3rxOmlEPTB;MD6wNFExPiEQvF2=	NHe2NXVUSU6JRWK=
NB13	M4PKTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHfJXVVKSzVyPUCuNFAyODdizszN	M1fVS3NCVkeHUh?=
NBsusSR	NV;ucZNOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXPIdVQzUUN3ME2wMlAxOTFizszN	M{OweXNCVkeHUh?=
LNCaP-Clone-FGC	NG\NXJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml\tTWM2OD1yLkCwNVEh\|ryP	MWjTRW5ITVJ?
EPLC-272H	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHfrcJRKSzVyPUCuNFAyOTFizszN	MmDrV2FPT0WU
KNS-62	MoLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFK0dWRKSzVyPUCuNFAyOTJizszN	NG\3fYxUSU6JRWK=
RERF-LC-MS	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{P0[2lEPTB;MD6wNFEyOyEQvF2=	MljzV2FPT0WU
LOXIMVI	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTBwMECxNVYh\|ryP	MlrYV2FPT0WU
KINGS-1	NVzOfYJTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVzPVoVQUUN3ME2wMlAxOTF5IN88US=>	MVXTRW5ITVJ?
T98G	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLufZhKSzVyPUCuNFAyOTdizszN	NYjSbldvW0GQR1XS
HCC1806	MmXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUDJR\|UxRTBwMECxNVgh\|ryP	MnyyV2FPT0WU
MZ1-PC	MnjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkDmTWM2OD1yLkCwNVE5KM7:TR?=	NXXUTHVGW0GQR1XS
RT-112	MnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TIV2lEPTB;MD6wNFEyQSEQvF2=	NYThTlFmW0GQR1XS
LK-2	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DIPWlEPTB;MD6wNFEzOSEQvF2=	MlvlV2FPT0WU
A375	M4jFZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXn0WlZjUUN3ME2wMlAxOTJzIN88US=>	M1HofHNCVkeHUh?=
SF268	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mle5TWM2OD1yLkCwNVIyKM7:TR?=	Mm\QV2FPT0WU
H9	NEKydW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTBwMECxNlQh\|ryP	NIPIO4NUSU6JRWK=
KYSE-410	NEjUPItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVzjRVVZUUN3ME2wMlAxOTJ2IN88US=>	MlmzV2FPT0WU
G-401	NEPuR3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHRTWM2OD1yLkCwNVI4KM7:TR?=	NIX0V41USU6JRWK=
SW982	M{X1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljlTWM2OD1yLkCwNVI4KM7:TR?=	Ml;oV2FPT0WU
D-423MG	M3vHVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jmXGlEPTB;MD6wNFE{KM7:TR?=	NF:xToFUSU6JRWK=
CAMA-1	MnTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTBwMECxN\|Eh\|ryP	NHjPbVNUSU6JRWK=
SCC-9	NEXXWlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjscY1qUUN3ME2wMlAxOTN{IN88US=>	MnfKV2FPT0WU
SAS	NHfEV\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2DVbmlEPTB;MD6wNFE{PCEQvF2=	NWTReG9oW0GQR1XS
KYSE-180	NU\jUJd7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1P6dGlEPTB;MD6wNFE{PSEQvF2=	NXvneVE1W0GQR1XS
EW-16	NWnob2g{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\PTWM2OD1yLkCwNVM2KM7:TR?=	M2O5[XNCVkeHUh?=
HD-MY-Z	NV70UZUxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTBwMECxOFEh\|ryP	MmDPV2FPT0WU
KYSE-450	MoSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zQUWlEPTB;MD6wNFE1OyEQvF2=	NWj6XnVkW0GQR1XS
LCLC-97TM1	Mn\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPC[m81UUN3ME2wMlAxOTR2IN88US=>	NVf5[\|B{W0GQR1XS
KS-1	NH;JfWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXfQT\|BZUUN3ME2wMlAxOTR2IN88US=>	M4TlWHNCVkeHUh?=
TI-73	NXnEZ2NIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTBwMECxOFQh\|ryP	MY\TRW5ITVJ?
A427	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEDwUW9KSzVyPUCuNFAyPDhizszN	M4XLSHNCVkeHUh?=
LB831-BLC	M3u3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTBwMECxOFgh\|ryP	NYLBOWN6W0GQR1XS
MG-63	MnH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\BTWM2OD1yLkCwNVUyKM7:TR?=	M3\sd3NCVkeHUh?=
PANC-03-27	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1fQZ2lEPTB;MD6wNFE2PCEQvF2=	NFWyN2lUSU6JRWK=
23132-87	M3uwcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnvYTWM2OD1yLkCwNVU2KM7:TR?=	NFzPcHBUSU6JRWK=
ES4	NFHCTI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWXNSoMxUUN3ME2wMlAxOTV3IN88US=>	MULTRW5ITVJ?
KP-4	M2[zOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1H3R2lEPTB;MD6wNFE2PiEQvF2=	NU[3V5NXW0GQR1XS
NCI-H1703	NX7VbXhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3Xwd2lEPTB;MD6wNFE2PyEQvF2=	MULTRW5ITVJ?
MCF7	NG\RWGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PkXmlEPTB;MD6wNFE3OSEQvF2=	Mm\XV2FPT0WU
A172	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGewdWNKSzVyPUCuNFAyPjNizszN	M2DRc3NCVkeHUh?=
CAL-39	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHtRmdKSzVyPUCuNFAyPjNizszN	MXPTRW5ITVJ?
Saos-2	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRTBwMECxOlgh\|ryP	MlTSV2FPT0WU
EW-11	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXz2fpJQUUN3ME2wMlAxOTZ7IN88US=>	M{CzdXNCVkeHUh?=
D-336MG	M3rXe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NInDZoRKSzVyPUCuNFAyPjlizszN	MknPV2FPT0WU
SW13	MnXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTBwMECxOlkh\|ryP	MX;TRW5ITVJ?
ME-180	NH3hOG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzJUmJKSzVyPUCuNFAyPjlizszN	MVzTRW5ITVJ?
SK-MEL-2	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYS0dVVkUUN3ME2wMlAxOTdizszN	NEez[3FUSU6JRWK=
697	NIC3NIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTBwMECxO\|Ih\|ryP	MV\TRW5ITVJ?
D-247MG	M1\K[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlraTWM2OD1yLkCwNVc{KM7:TR?=	Mn3mV2FPT0WU
EoL-1-cell	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PSR2lEPTB;MD6wNFE4OyEQvF2=	MlLNV2FPT0WU
MV-4-11	NU\TXFV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1[5WGlEPTB;MD6wNFE4PCEQvF2=	NFSwZmFUSU6JRWK=
U-2-OS	NXTW[5hiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF23OZJKSzVyPUCuNFAyPzVizszN	NX6yW4xHW0GQR1XS
NCI-H526	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTBwMECxO\|Yh\|ryP	NGfV[lNUSU6JRWK=
SK-NEP-1	NFzOcGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFP1dpVKSzVyPUCuNFAyPzZizszN	NXrXbY1pW0GQR1XS
DB	NWDDXJE3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInNPWVKSzVyPUCuNFAyPzhizszN	MlvEV2FPT0WU
GCT	M4L5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\kenY5UUN3ME2wMlAxOThizszN	MUjTRW5ITVJ?
HCT-116	M1jRWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\vTWM2OD1yLkCwNVgyKM7:TR?=	NWqzcI8xW0GQR1XS
AU565	M{K4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTiTWM2OD1yLkCwNVgyKM7:TR?=	NYX4XHQ5W0GQR1XS
KALS-1	NWfDXHc4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTBwMECxPFEh\|ryP	NV:2SWxOW0GQR1XS
C2BBe1	NYPjd2xUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI[2cHpKSzVyPUCuNFAyQDJizszN	M2DtT3NCVkeHUh?=
Becker	NUTHc2ltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGrFVWZKSzVyPUCuNFAyQDNizszN	NF7MZYxUSU6JRWK=
647-V	NGLQWGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTBwMECxPFQh\|ryP	NX;adVByW0GQR1XS
NCI-H2122	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjod3NKSzVyPUCuNFAyQDRizszN	MlHhV2FPT0WU
SBC-5	M1uyfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIDOOmtKSzVyPUCuNFAyQDdizszN	NEH1O3FUSU6JRWK=
NB17	MnvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF\PSZVKSzVyPUCuNFAyQDlizszN	NEHBTY9USU6JRWK=
MHH-PREB-1	NXu3WWF7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{fpbmlEPTB;MD6wNFE5QSEQvF2=	M2rHUnNCVkeHUh?=
M14	Ml34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXe1WmtRUUN3ME2wMlAxOTlzIN88US=>	NHzkUVRUSU6JRWK=
NCI-H1048	Mm\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1O3cmlEPTB;MD6wNFE6OiEQvF2=	M1rjN3NCVkeHUh?=
CTB-1	M33nRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M33ZfmlEPTB;MD6wNFE6OiEQvF2=	NYTiNJIzW0GQR1XS
SK-PN-DW	MlvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPCUIhKSzVyPUCuNFAyQTRizszN	NGfBXJVUSU6JRWK=
H4	M{LRd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGTMTGZKSzVyPUCuNFAyQTZizszN	NFvhWGpUSU6JRWK=
NCI-SNU-1	M13yRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVrJOWFpUUN3ME2wMlAxOTl5IN88US=>	MV\TRW5ITVJ?
M059J	NF3SWWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIHNcHRKSzVyPUCuNFAyQThizszN	MoXxV2FPT0WU
OVCAR-5	Ml7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4DLdGlEPTB;MD6wNFE6QSEQvF2=	NX3DSnZzW0GQR1XS
SK-MEL-28	M{DTemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlv0TWM2OD1yLkCwNlA{KM7:TR?=	NYHaWnJ7W0GQR1XS
PC-14	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHTfpJKSzVyPUCuNFAzODlizszN	MlHDV2FPT0WU
OVCAR-8	Mkm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MonzTWM2OD1yLkCwNlEzKM7:TR?=	NV\zPW5MW0GQR1XS
BB49-HNC	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLye4V1UUN3ME2wMlAxOjF{IN88US=>	MljKV2FPT0WU
EFM-19	NVLhZ2tjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPKfHYxUUN3ME2wMlAxOjF3IN88US=>	NEThU2tUSU6JRWK=
BHY	NGHhbWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;PXY51UUN3ME2wMlAxOjF4IN88US=>	M2P1b3NCVkeHUh?=
SW756	NXnsR4c2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTBwMECyNVYh\|ryP	NIHJ[nFUSU6JRWK=
TE-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTBwMECyNVYh\|ryP	NFvjdHBUSU6JRWK=
NCI-H2452	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1nPTGlEPTB;MD6wNFIyPiEQvF2=	NG[zTYZUSU6JRWK=
NCI-H1581	NVXUeJFMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHfGV2RKSzVyPUCuNFAzOTdizszN	MYTTRW5ITVJ?
COR-L23	NXy1fJBqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlvJTWM2OD1yLkCwNlIh\|ryP	M2DmR3NCVkeHUh?=
RXF393	NVjy[3h{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrTTWM2OD1yLkCwNlIzKM7:TR?=	MnTzV2FPT0WU
BFTC-909	MkjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXfsbIdzUUN3ME2wMlAxOjJ3IN88US=>	M2Pz[HNCVkeHUh?=
IST-MEL1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVvKNmJ5UUN3ME2wMlAxOjJ3IN88US=>	NIXQbXRUSU6JRWK=
NCI-H650	MlrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmPITWM2OD1yLkCwNlI2KM7:TR?=	MnP2V2FPT0WU
SK-UT-1	NUTzcJRJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGS1V3JKSzVyPUCuNFAzOjZizszN	MojHV2FPT0WU
GOTO	MnvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDDTWM2OD1yLkCwNlI4KM7:TR?=	NVr2XJFpW0GQR1XS
TYK-nu	NGizeFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTBwMECyN\|Ih\|ryP	MUDTRW5ITVJ?
JVM-3	NXPmV3p[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{L6T2lEPTB;MD6wNFI{OyEQvF2=	MWHTRW5ITVJ?
SK-MES-1	NFn4[W5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\LNlZKSzVyPUCuNFAzOzNizszN	NWnRcoExW0GQR1XS
SK-HEP-1	NHPZWINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LnS2lEPTB;MD6wNFI{PCEQvF2=	NITBUXBUSU6JRWK=
J-RT3-T3-5	NUj4Z2FkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjlbVFKSzVyPUCuNFAzOzVizszN	NE\QWW5USU6JRWK=
A673	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTBwMECyN\|Uh\|ryP	M3XKS3NCVkeHUh?=
NCI-H446	NFfDd4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTBwMECyOFMh\|ryP	MXvTRW5ITVJ?
RPMI-2650	MoL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDTTWM2OD1yLkCwNlQ3KM7:TR?=	NYnZR2FFW0GQR1XS
HCE-4	NUTWTGJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIPXfVVKSzVyPUCuNFAzPDdizszN	NFTQc2tUSU6JRWK=
KGN	NVLGNIc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTBwMECyOFch\|ryP	MYHTRW5ITVJ?
U251	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLtd4lZUUN3ME2wMlAxOjVizszN	MVzTRW5ITVJ?
BxPC-3	NX;r[2ZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHOZlBKSzVyPUCuNFAzPTFizszN	MnrVV2FPT0WU
VMRC-RCZ	M2LoRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3TSfGlEPTB;MD6wNFI2OiEQvF2=	M3XFN3NCVkeHUh?=
TE-10	Ml3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{ntUGlEPTB;MD6wNFI2PCEQvF2=	NFTGZXVUSU6JRWK=
OC-314	M{HoRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTBwMECyOVYh\|ryP	MkTwV2FPT0WU
NCI-H1437	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTBwMECyOkDPxE1?	NVHLSnVHW0GQR1XS
SNU-387	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTBwMECyOlEh\|ryP	NUn4bG1qW0GQR1XS
A388	M3jFWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlPPTWM2OD1yLkCwNlY2KM7:TR?=	MkPwV2FPT0WU
C-33-A	NUe4VmZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTBwMECyOlYh\|ryP	MmLWV2FPT0WU
CAL-51	NF\J[JNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2HiWmlEPTB;MD6wNFI4OSEQvF2=	M2DoRXNCVkeHUh?=
Hs-578-T	Mn7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4rmRmlEPTB;MD6wNFI4OiEQvF2=	MlHZV2FPT0WU
MDA-MB-415	NWDONYtZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlzFTWM2OD1yLkCwNlc1KM7:TR?=	NEf5[5JUSU6JRWK=
SW1417	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnzbWxtUUN3ME2wMlAxOjd4IN88US=>	NUnEdlk6W0GQR1XS
HCC70	M2ft[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXpNI5KSzVyPUCuNFAzPzdizszN	NWDBOFV{W0GQR1XS
ES3	NXLLflJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHL0RpZKSzVyPUCuNFAzPzdizszN	NYDDS243W0GQR1XS
KYSE-270	MmLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTBwMECyO\|gh\|ryP	MUDTRW5ITVJ?
HT-29	MkTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{mxdGlEPTB;MD6wNFI5KM7:TR?=	NFf1cWVUSU6JRWK=
MDA-MB-361	NIH1SnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWL1ZlhKUUN3ME2wMlAxOjhzIN88US=>	NEjOcXdUSU6JRWK=
RPMI-8866	NF6xRlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTBwMECyPFEh\|ryP	M{fObnNCVkeHUh?=
JEG-3	NXW1S2ZQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFraUItKSzVyPUCuNFAzQDJizszN	NWP2[JVjW0GQR1XS
HT-3	M2e1cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWL1ZZF2UUN3ME2wMlAxOjh{IN88US=>	NXHydZJyW0GQR1XS
HTC-C3	NYD3ZWlMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnLDTWM2OD1yLkCwNlg2KM7:TR?=	M1j3VnNCVkeHUh?=
NCI-H209	M362NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\FTWM2OD1yLkCwNlg3KM7:TR?=	MoXjV2FPT0WU
SKG-IIIa	MkHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1\QcWlEPTB;MD6wNFI5PiEQvF2=	M2\ZU3NCVkeHUh?=
SW962	MmG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrNOVM4UUN3ME2wMlAxOjl\|IN88US=>	MYjTRW5ITVJ?
LCLC-103H	M{ewTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUWwWHp1UUN3ME2wMlAxOjl\|IN88US=>	NX\HeJRGW0GQR1XS
DOK	NYKyW4ZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIrVcYlKSzVyPUCuNFAzQTRizszN	M4nhUXNCVkeHUh?=
SW1088	M{jGV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUWxfZFRUUN3ME2wMlAxOjl3IN88US=>	NV;Nd4sxW0GQR1XS
GP5d	NWL1RlJuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33zOGlEPTB;MD6wNFI6PiEQvF2=	MWTTRW5ITVJ?
EW-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX3tXXNnUUN3ME2wMlAxOjl6IN88US=>	MlfIV2FPT0WU
CP66-MEL	MlXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWn4NHBPUUN3ME2wMlAxOyEQvF2=	NV3HZ3NkW0GQR1XS
DEL	NF23TZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXzH[FRZUUN3ME2wMlAxOzBzIN88US=>	NG\ZcWVUSU6JRWK=
DU-4475	MmD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1nNd2lEPTB;MD6wNFMxOiEQvF2=	M4OyWXNCVkeHUh?=
HEC-1	MmrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTBwMECzNFMh\|ryP	NVHIXphFW0GQR1XS
U031	Mk[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTBwMECzNFch\|ryP	NWHhXG02W0GQR1XS
BB65-RCC	MlywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGGxUnpKSzVyPUCuNFA{ODhizszN	NU\JTYdRW0GQR1XS
NUGC-3	MmqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTBwMECzNFgh\|ryP	NYPYTmZ2W0GQR1XS
IST-SL1	M2fadGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HZO2lEPTB;MD6wNFMyOiEQvF2=	MoDvV2FPT0WU
LS-411N	MmPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{jESWlEPTB;MD6wNFMyPCEQvF2=	NI\VNHhUSU6JRWK=
22RV1	NHLBcoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYGzWlRrUUN3ME2wMlAxOzF3IN88US=>	NXjxTI5OW0GQR1XS
MKN28	NWTtTYZyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPRSmpKSzVyPUCuNFA{OTdizszN	MXPTRW5ITVJ?
ONS-76	M4\kOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2T1cmlEPTB;MD6wNFMzOiEQvF2=	MXXTRW5ITVJ?
SH-4	NFfwe4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33TcGlEPTB;MD6wNFMzOiEQvF2=	MmXQV2FPT0WU
MIA-PaCa-2	M13TcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTjdW9vUUN3ME2wMlAxOzJ2IN88US=>	NHjWdJpUSU6JRWK=
CaR-1	NYrOO41mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTBwMECzNlch\|ryP	Mn;ZV2FPT0WU
AGS	NULkOVlTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTBwMECzNlgh\|ryP	MX3TRW5ITVJ?
SF126	M3LVNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTBwMECzNlkh\|ryP	M{HWSHNCVkeHUh?=
UACC-62	MonNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTBwMECzN{DPxE1?	Mo\vV2FPT0WU
NCI-H28	NWnMWnpzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUTMOlh4UUN3ME2wMlAxOzN2IN88US=>	NEHhZWhUSU6JRWK=
A2780	M1XNXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLZTWM2OD1yLkCwN\|M2KM7:TR?=	M{nRXHNCVkeHUh?=
CTV-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7qRXVKSzVyPUCuNFA{OzdizszN	M{DvXXNCVkeHUh?=
LC-2-ad	NHHtV5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkPjTWM2OD1yLkCwN\|Qh\|ryP	NYntN5ZjW0GQR1XS
NCI-H1770	MlG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoPYTWM2OD1yLkCwN\|QzKM7:TR?=	Ml7CV2FPT0WU
HuO9	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHrROJBKSzVyPUCuNFA{PDZizszN	NGiyc41USU6JRWK=
U-266	NViweZE1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlqzTWM2OD1yLkCwN\|Q5KM7:TR?=	MXPTRW5ITVJ?
MLMA	M4X4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGXKN3ZKSzVyPUCuNFA{PTVizszN	M2LmZ3NCVkeHUh?=
U-87-MG	MnPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17mUWlEPTB;MD6wNFM2PSEQvF2=	NInEbolUSU6JRWK=
GI-ME-N	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTBwMECzOVgh\|ryP	NU\5XY9SW0GQR1XS
HL-60	M2ThUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnTLTWM2OD1yLkCwN\|U6KM7:TR?=	Mn6yV2FPT0WU
EGI-1	NWTYN4dJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfZfGxQUUN3ME2wMlAxOzZ{IN88US=>	M3rHenNCVkeHUh?=
NCI-H23	NXHidFQxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;lZZBKSzVyPUCuNFA{PjRizszN	MVTTRW5ITVJ?
NCI-H226	Mk\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTBwMECzOlgh\|ryP	NUThcWlZW0GQR1XS
NCI-H520	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEW4XWlKSzVyPUCuNFA{PzJizszN	NUnTPG14W0GQR1XS
L-363	NUnpdnF4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NITOcZNKSzVyPUCuNFA{PzZizszN	MXjTRW5ITVJ?
CAL-12T	NYrucpVST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUSwUnp2UUN3ME2wMlAxOzd4IN88US=>	M3TGTHNCVkeHUh?=
BT-20	M3;DPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF;veoVKSzVyPUCuNFA{PzZizszN	M{LhNXNCVkeHUh?=
SNB75	M{jwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTBwMECzPFEh\|ryP	M{G3T3NCVkeHUh?=
A4-Fuk	M1XSTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{\CVmlEPTB;MD6wNFM6KM7:TR?=	MX7TRW5ITVJ?
BE-13	NHmxZWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoDkTWM2OD1yLkCwN\|k{KM7:TR?=	MmTXV2FPT0WU
NCI-H1395	MmLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWLxRVNZUUN3ME2wMlAxOzl4IN88US=>	NIfZO5RUSU6JRWK=
SW620	NUDieVNCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXqwZWpnUUN3ME2wMlAxOzl5IN88US=>	NHG3c\|NUSU6JRWK=
KNS-81-FD	NHHJWnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTBwMECzPVkh\|ryP	NIToZY9USU6JRWK=
RD	M33WUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljTTWM2OD1yLkCwOEDPxE1?	NFX3PFlUSU6JRWK=
HLE	M4O5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUDJR\|UxRTBwMEC0NFUh\|ryP	M3r5eXNCVkeHUh?=
OVCAR-3	NUPEZ5ZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVyz[2RnUUN3ME2wMlAxPDB5IN88US=>	MnrWV2FPT0WU
KM12	NVvldmd4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFj2R4xKSzVyPUCuNFA1ODhizszN	MVfTRW5ITVJ?
HCC2998	NV3ofmhpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmSxTWM2OD1yLkCwOFA5KM7:TR?=	MULTRW5ITVJ?
D-502MG	NGPzU2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmrMTWM2OD1yLkCwOFEh\|ryP	NEGyS2ZUSU6JRWK=
KNS-42	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{OxOWlEPTB;MD6wNFQyOiEQvF2=	NFXWe4FUSU6JRWK=
LS-123	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vyOmlEPTB;MD6wNFQzPSEQvF2=	MkjQV2FPT0WU
SiHa	Mom2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXfDWGRDUUN3ME2wMlAxPDNizszN	M1K4T3NCVkeHUh?=
T47D	NVXVcVk6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2XGbmlEPTB;MD6wNFQ{OSEQvF2=	MmjvV2FPT0WU
EW-24	NF;vVYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3vse2lEPTB;MD6wNFQ{OyEQvF2=	NXzPO3ZwW0GQR1XS
CAL-120	NXm3NmhDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmHOTWM2OD1yLkCwOFM2KM7:TR?=	MYjTRW5ITVJ?
JAR	NFjPVYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkP0TWM2OD1yLkCwOFM4KM7:TR?=	NUHMTopDW0GQR1XS
QIMR-WIL	NYDB[I9WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLYfoZKSzVyPUCuNFA1OzhizszN	MUnTRW5ITVJ?
OCUB-M	MmL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTBwMEC0N\|gh\|ryP	MU\TRW5ITVJ?
Calu-6	Mm[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkSzTWM2OD1yLkCwOFQ4KM7:TR?=	MkfWV2FPT0WU
MDA-MB-453	NVjDV3pNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4TnPWlEPTB;MD6wNFQ2OSEQvF2=	NXXXWII3W0GQR1XS
MKN45	NX3QT4VTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTBwMEC0OVMh\|ryP	MUjTRW5ITVJ?
ECC10	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mly2TWM2OD1yLkCwOFYh\|ryP	NGn2WoRUSU6JRWK=
RVH-421	M13oUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlL0TWM2OD1yLkCwOFYyKM7:TR?=	Ml[4V2FPT0WU
TGBC11TKB	NFLiNYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fuZWlEPTB;MD6wNFQ3QSEQvF2=	NEm3RoZUSU6JRWK=
MOLT-4	NVrucHQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUCybpNEUUN3ME2wMlAxPDdzIN88US=>	MoLSV2FPT0WU
LN-405	MkWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUH2fYl5UUN3ME2wMlAxPDh{IN88US=>	MYDTRW5ITVJ?
S-117	NHvUXYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml;XTWM2OD1yLkCwOFg3KM7:TR?=	NVvxeVdNW0GQR1XS
RPMI-8226	M2XMRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTBwMEC0PVch\|ryP	NYDuRWRmW0GQR1XS
KYSE-150	NXG4cVB6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3XTWM2OD1yLkCwOFk6KM7:TR?=	NVnBeoM1W0GQR1XS
NCI-H1666	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4qwcmlEPTB;MD6wNFUxPSEQvF2=	MnTOV2FPT0WU
Mewo	NYX4fplpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIfselZKSzVyPUCuNFA2ODVizszN	NU\GVIhiW0GQR1XS
AN3-CA	M362emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2[3PWlEPTB;MD6wNFUxPyEQvF2=	Moe4V2FPT0WU
COLO-680N	MnrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzXTWM2OD1yLkCwOVA5KM7:TR?=	NV;l[lhZW0GQR1XS
FADU	NWXqNoRDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7mNWFsUUN3ME2wMlAxPTFizszN	NYXHZXV{W0GQR1XS
GB-1	NIH3bIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1mybGlEPTB;MD6wNFUyOSEQvF2=	MlPjV2FPT0WU
KASUMI-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MonMTWM2OD1yLkCwOVEyKM7:TR?=	MWTTRW5ITVJ?
NOMO-1	NIqzUIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXj6UXdYUUN3ME2wMlAxPTF\|IN88US=>	M2jCdXNCVkeHUh?=
BV-173	NH\nSJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYi2cGZnUUN3ME2wMlAxPTNizszN	MWLTRW5ITVJ?
RO82-W-1	NVHB[IxiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVXJR\|UxRTBwMEC1N\|Eh\|ryP	NVPIbI5{W0GQR1XS
LB2241-RCC	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\3bGlEPTB;MD6wNFU{OSEQvF2=	MmKzV2FPT0WU
NCI-H2170	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn3YTWM2OD1yLkCwOVM2KM7:TR?=	NWHkSpl5W0GQR1XS
SK-N-AS	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFnSZ2hKSzVyPUCuNFA2OzVizszN	MXzTRW5ITVJ?
NCI-H1651	NWPEZ4ZST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4PDNmlEPTB;MD6wNFU1KM7:TR?=	NFXwTFZUSU6JRWK=
NCI-SNU-5	M1fRWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;HNWlEPTB;MD6wNFU1PSEQvF2=	MYnTRW5ITVJ?
SN12C	MlXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{KwUmlEPTB;MD6wNFU2KM7:TR?=	MVXTRW5ITVJ?
KY821	NFqxfIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{S4eWlEPTB;MD6wNFU2OSEQvF2=	M{n0XHNCVkeHUh?=
SW1573	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTBwMEC1OVQh\|ryP	Mn:0V2FPT0WU
OE19	NE\6W4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1TTemlEPTB;MD6wNFU2QSEQvF2=	NID6R5JUSU6JRWK=
MPP-89	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\TeZJzUUN3ME2wMlAxPTZ5IN88US=>	MVTTRW5ITVJ?
HuCCT1	MlrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLYTWM2OD1yLkCwOVY5KM7:TR?=	MofNV2FPT0WU
SW1783	NVGxNFRQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlm0TWM2OD1yLkCwOVch\|ryP	NYLyTpFCW0GQR1XS
8305C	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXjRXGE1UUN3ME2wMlAxPTd4IN88US=>	NEjnPGZUSU6JRWK=
OVCAR-4	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTBwMEC1PFYh\|ryP	MXnTRW5ITVJ?
MMAC-SF	M3rXZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHOyWJhKSzVyPUCuNFA2QDZizszN	M1jaTHNCVkeHUh?=
COLO-824	Mm\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXj3W2VYUUN3ME2wMlAxPTlizszN	M2nN[nNCVkeHUh?=
HCC38	NI\Ld2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTBwMEC2JO69VQ>?	NVfiOWlKW0GQR1XS
NCI-H1648	NXn2Not{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkTJTWM2OD1yLkCwOlAyKM7:TR?=	MkHYV2FPT0WU
NCI-H1573	NIHOfIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVXJR\|UxRTBwMEC2NFch\|ryP	MVHTRW5ITVJ?
MFM-223	M3rUcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTBwMEC2NVYh\|ryP	MV;TRW5ITVJ?
NCI-H810	NF[xbGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3QSFc1UUN3ME2wMlAxPjJ{IN88US=>	Mm\qV2FPT0WU
EM-2	M1jqSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXLsWVROUUN3ME2wMlAxPjJ\|IN88US=>	MULTRW5ITVJ?
D-283MED	NWfIbpk6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NULubJRpUUN3ME2wMlAxPjJ2IN88US=>	NUiwVlBsW0GQR1XS
NCI-H1755	NXrC[2E2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnzMTWM2OD1yLkCwOlI1KM7:TR?=	MYHTRW5ITVJ?
KYSE-70	M3\ZOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnrkTWM2OD1yLkCwOlI1KM7:TR?=	MXzTRW5ITVJ?
SW626	M3iweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkLnTWM2OD1yLkCwOlI1KM7:TR?=	NHrkXYJUSU6JRWK=
WM-115	M3HxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWTidWxwUUN3ME2wMlAxPjJ5IN88US=>	NXiydnpVW0GQR1XS
NB69	NFf1S2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTBwMEC2Nlkh\|ryP	Mk\2V2FPT0WU
DOHH-2	MnLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTBwMEC2N{DPxE1?	MlLXV2FPT0WU
MEL-JUSO	NXfPcGJLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLQTWM2OD1yLkCwOlM6KM7:TR?=	NH\PW5ZUSU6JRWK=
IGR-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2DBOGlEPTB;MD6wNFY1OSEQvF2=	NVr4PZk5W0GQR1XS
ACN	NW\tcVc4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvBXGJKSzVyPUCuNFA3PDRizszN	MmDCV2FPT0WU
KARPAS-45	M1;JfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTBwMEC2OVIh\|ryP	MYDTRW5ITVJ?
HC-1	NULWcXdZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHf6VGFKSzVyPUCuNFA3PTZizszN	NW[z[nNwW0GQR1XS
MZ2-MEL	NHewVFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDEc2NLUUN3ME2wMlAxPjV6IN88US=>	MkPMV2FPT0WU
NCI-H1355	NXi2fHJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTBwMEC2O\|kh\|ryP	NHTVWXlUSU6JRWK=
HuP-T4	NXyyXGhQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIf2eYtKSzVyPUCuNFA3PzlizszN	MnPsV2FPT0WU
AsPC-1	NIe0eoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\rRm1KSzVyPUCuNFA3QDNizszN	NILj[5VUSU6JRWK=
SCC-15	M33nRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3\sbWlEPTB;MD6wNFY5QSEQvF2=	NV\EUId7W0GQR1XS
CP50-MEL-B	NGr2PFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVTsS5ljUUN3ME2wMlAxPjl\|IN88US=>	MXrTRW5ITVJ?
DMS-114	NWixfGJjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTBwMEC2PVYh\|ryP	MW\TRW5ITVJ?
KYSE-520	NWLXRm41T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTBwMEC3JO69VQ>?	M4nWWnNCVkeHUh?=
NCI-H2228	NHG1WpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTBwMEC3NlUh\|ryP	MXLTRW5ITVJ?
COLO-829	MoDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXvJR\|UxRTBwMEC3NlUh\|ryP	NH;JTIVUSU6JRWK=
NCI-H2052	NWHiZow6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{HCdWlEPTB;MD6wNFczPyEQvF2=	NGntT\|dUSU6JRWK=
HOP-92	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTBwMEC3N{DPxE1?	NFX1WJFUSU6JRWK=
MDA-MB-231	MlHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnfuTWM2OD1yLkCwO\|Mh\|ryP	NH7HemlUSU6JRWK=
SK-MEL-30	MoPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlz3TWM2OD1yLkCwO\|MzKM7:TR?=	MXTTRW5ITVJ?
NCI-H2087	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLRTWM2OD1yLkCwO\|Q5KM7:TR?=	MkPDV2FPT0WU
SW900	MkTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDxZ3pKSzVyPUCuNFA4PTVizszN	M1izbXNCVkeHUh?=
NCI-H358	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkWwTWM2OD1yLkCwO\|U5KM7:TR?=	NYn3SJdQW0GQR1XS
NCI-H2126	M2rXWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1PlV2lEPTB;MD6wNFc4OyEQvF2=	MVHTRW5ITVJ?
TGBC24TKB	NVziR3hMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTBwMEC3PFEh\|ryP	NWjEdFhHW0GQR1XS
786-0	M1fmUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVXPPYFtUUN3ME2wMlAxPzh4IN88US=>	M1noPHNCVkeHUh?=
no-10	NILFeGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLm[GpKSzVyPUCuNFA4QDhizszN	Mnr3V2FPT0WU
SCH	M{XKUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1jkSGlEPTB;MD6wNFgyQCEQvF2=	NGLzZnVUSU6JRWK=
COLO-741	NXTPdGVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPMTWM2OD1yLkCwPFIh\|ryP	NInORWNUSU6JRWK=
NCI-H82	MkPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3TcndQUUN3ME2wMlAxQDJ{IN88US=>	MlL3V2FPT0WU
MOLT-16	M2Dmd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTBwMEC4Nlch\|ryP	M4exfnNCVkeHUh?=
IST-MES1	MoPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIHjem9KSzVyPUCuNFA5PCEQvF2=	NH:0d29USU6JRWK=
NCI-H1623	MojzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEC3ZopKSzVyPUCuNFA5PTZizszN	NUe4SWc3W0GQR1XS
NCI-H1299	M2\sSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTBwMEC4OVch\|ryP	NHLwNXlUSU6JRWK=
SNU-423	NGrHR4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fYc2lEPTB;MD6wNFg2PyEQvF2=	MV\TRW5ITVJ?
ALL-PO	NXLYVVdFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3e2Z2lEPTB;MD6wNFg3KM7:TR?=	NGiwNJJUSU6JRWK=
DK-MG	M{fMU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV75SVVPUUN3ME2wMlAxQDZizszN	MUTTRW5ITVJ?
LB1047-RCC	NGK5SJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTBwMEC4PEDPxE1?	MXfTRW5ITVJ?
OMC-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEH0O2hKSzVyPUCuNFA6ODZizszN	NIrZ[ZpUSU6JRWK=
TGBC1TKB	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\mTWM2OD1yLkCwPVEh\|ryP	MoHWV2FPT0WU
DBTRG-05MG	MnXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTBwMEC5NVch\|ryP	NIDIbI9USU6JRWK=
HPAF-II	MkftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTBwMEC5NlYh\|ryP	M{\CWXNCVkeHUh?=
A204	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\4RnZKSzVyPUCuNFA6OzRizszN	M1noZ3NCVkeHUh?=
TK10	M4S1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIS2XIZKSzVyPUCuNFA6PzdizszN	M2X1WnNCVkeHUh?=
BHT-101	MojHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2rm[2lEPTB;MD6wNFk5KM7:TR?=	NVqzcY5zW0GQR1XS
SK-N-DZ	M2PwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{P0RWlEPTB;MD6wNFk5OyEQvF2=	NX3LeIZnW0GQR1XS
ChaGo-K-1	Mk\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrhb5FLUUN3ME2wMlAxQTh6IN88US=>	NHXpO29USU6JRWK=
NCI-H661	MnHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTBwMEGwNFUh\|ryP	NHHvVFVUSU6JRWK=
AM-38	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlW2TWM2OD1yLkCxNFI1KM7:TR?=	NUDuNYxMW0GQR1XS
ML-2	NVLxZYZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\BTWM2OD1yLkCxNFI6KM7:TR?=	Ml[1V2FPT0WU
TCCSUP	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWLJR\|UxRTBwMEGwN\|Yh\|ryP	NUm0eXJbW0GQR1XS
SW1990	MmHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4e4dGlEPTB;MD6wNVA1PyEQvF2=	NVvzbmJPW0GQR1XS
HCC1395	NUm1eHkzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1XPcWlEPTB;MD6wNVA2PiEQvF2=	NWrCPWhlW0GQR1XS
PANC-10-05	NYj5XlZuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvl[m1KSzVyPUCuNFExPTZizszN	NXPWdpZwW0GQR1XS
CAKI-1	MnraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEG2U5RKSzVyPUCuNFExPzNizszN	MnnIV2FPT0WU
HuP-T3	M4e5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTBwMEGwO\|ch\|ryP	M3TEbHNCVkeHUh?=
HT-1197	MkDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HZS2lEPTB;MD6wNVA5PCEQvF2=	MVzTRW5ITVJ?
MOLT-13	NWjLVo1xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M17JOmlEPTB;MD6wNVA5PiEQvF2=	NFfscHhUSU6JRWK=
NCI-H1563	MnHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LJXGlEPTB;MD6wNVA5PyEQvF2=	NV;IOJd[W0GQR1XS
NCI-N87	M1LONGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTBwMEGwPVMh\|ryP	NFLCbZlUSU6JRWK=
LB373-MEL-D	NXv1WXcyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4\6R2lEPTB;MD6wNVA6PCEQvF2=	MmHhV2FPT0WU
EFO-21	MmnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTBwMEGxJO69VQ>?	NXX5cWI1W0GQR1XS
LU-134-A	NYjuWVB3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVzneYNPUUN3ME2wMlAyOTB{IN88US=>	Ml3vV2FPT0WU
DU-145	NF3VV5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXHUZ4hDUUN3ME2wMlAyOTB5IN88US=>	NH3RUFVUSU6JRWK=
SF295	NV7qdJp3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnPTWM2OD1yLkCxNVI3KM7:TR?=	MXPTRW5ITVJ?
ABC-1	NUjFcYFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\GN5BKSzVyPUCuNFEyPDZizszN	M1zvR3NCVkeHUh?=
TE-6	NFfWT5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTBwMEGxOFgh\|ryP	Ml3pV2FPT0WU
GAK	NXXLeo1PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVXJR\|UxRTBwMEGxOVgh\|ryP	MkK2V2FPT0WU
LU-139	NUeyS2QyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInCSnJKSzVyPUCuNFEyPjZizszN	M17GcnNCVkeHUh?=
EW-18	M3XoXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTBwMEGxOlkh\|ryP	NHflW\|JUSU6JRWK=
MSTO-211H	NFXTZY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGPVS5VKSzVyPUCuNFEyPzNizszN	NX\TVm9{W0GQR1XS
KU812	NUHXe\|BHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTBwMEGxPVgh\|ryP	NGXpdWhUSU6JRWK=
NCI-H441	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;yTWM2OD1yLkCxNVk5KM7:TR?=	MlPpV2FPT0WU
LU-99A	MnXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYfNeYhpUUN3ME2wMlAyOiEQvF2=	MWXTRW5ITVJ?
NB10	NILENpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\M[IhGUUN3ME2wMlAyOjB7IN88US=>	MYTTRW5ITVJ?
NCI-H1650	M3TTdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRTBwMEGyNlkh\|ryP	NX7QdnkyW0GQR1XS
YAPC	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MknRTWM2OD1yLkCxNlM4KM7:TR?=	NUfHToJzW0GQR1XS
HT55	NEXLNVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\JeHZCUUN3ME2wMlAyOjR{IN88US=>	M1nvW3NCVkeHUh?=
NB7	M4XFSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjCTWM2OD1yLkCxNlQ{KM7:TR?=	M2rqVHNCVkeHUh?=
NCI-H2030	M1vBbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvHTWM2OD1yLkCxNlU1KM7:TR?=	Mk\GV2FPT0WU
EW-22	M3foT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3m5VGlEPTB;MD6wNVI2PiEQvF2=	MVTTRW5ITVJ?
UMC-11	NHXyclhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLyTWM2OD1yLkCxNlg{KM7:TR?=	M3\uUHNCVkeHUh?=
MKN7	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWrLcYc3UUN3ME2wMlAyOjh\|IN88US=>	MYTTRW5ITVJ?
OE33	NFT5SYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jZNmlEPTB;MD6wNVMh\|ryP	NYnHS4NtW0GQR1XS
SK-LU-1	M{[5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzXdXJKSzVyPUCuNFE{OjRizszN	MoW3V2FPT0WU
LAMA-84	NXzjTnJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoTJTWM2OD1yLkCxN\|I5KM7:TR?=	M13nOnNCVkeHUh?=
IA-LM	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTBwMEGzN{DPxE1?	Mn;OV2FPT0WU
HuH-7	MkPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGfPfppKSzVyPUCuNFE{PTRizszN	NWPBT491W0GQR1XS
J82	NFzzZ\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{SwN2lEPTB;MD6wNVM6KM7:TR?=	M3ntTHNCVkeHUh?=
CFPAC-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTBwMEG0NFYh\|ryP	MW\TRW5ITVJ?
MN-60	MknyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTBwMEG0Nlkh\|ryP	NV\hSo5kW0GQR1XS
A704	MlfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWL2TmdCUUN3ME2wMlAyPDN6IN88US=>	M12wO3NCVkeHUh?=
SW684	NInhSo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXz3d5FoUUN3ME2wMlAyPDV{IN88US=>	MXXTRW5ITVJ?
NOS-1	NXTmRZViT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHoR\|NKSzVyPUCuNFE1PiEQvF2=	M4X4cXNCVkeHUh?=
U-118-MG	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGDrcI1KSzVyPUCuNFE1PyEQvF2=	MoP1V2FPT0WU
NCI-H596	NHjN[3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlL5TWM2OD1yLkCxOFc4KM7:TR?=	NXmwVWN3W0GQR1XS
RS4-11	NGPndJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWPXfpl{UUN3ME2wMlAyPTF4IN88US=>	MmHsV2FPT0WU
KP-N-YS	NUjaXnE4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnSZmhSUUN3ME2wMlAyPTJ\|IN88US=>	M2j5OXNCVkeHUh?=
MS-1	NY[zWWVXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfUV4dHUUN3ME2wMlAyPTR3IN88US=>	NVnCcodYW0GQR1XS
A101D	NYLBS4IzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3rVU2lEPTB;MD6wNVU1QSEQvF2=	M3HtVnNCVkeHUh?=
DSH1	Mni2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWi4RoIzUUN3ME2wMlAyPiEQvF2=	MnfYV2FPT0WU
CAS-1	NH\kOZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVzMUHg1UUN3ME2wMlAyPjB7IN88US=>	NX6wcHNKW0GQR1XS
NCI-H2347	NFX5WINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{XlO2lEPTB;MD6wNVY{PiEQvF2=	MoO5V2FPT0WU
T-24	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTBwMEG3NFUh\|ryP	M1LRfnNCVkeHUh?=
MEG-01	NWriUpV{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYLmcFlGUUN3ME2wMlAyPzN5IN88US=>	NEm3fGhUSU6JRWK=
NCI-H2291	M2S3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4SxdWlEPTB;MD6wNVg{QCEQvF2=	M3;JeXNCVkeHUh?=
SW872	NEXLd4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXiyUmlFUUN3ME2wMlAyQDZ5IN88US=>	NEHPR5lUSU6JRWK=
no-11	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml[xTWM2OD1yLkCxPFg4KM7:TR?=	NGrxR3NUSU6JRWK=
NB5	M1v0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYrCU\|Z6UUN3ME2wMlAyQDlzIN88US=>	MWXTRW5ITVJ?
MZ7-mel	Mm\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInrTYRKSzVyPUCuNFE6OzRizszN	NEjGfm5USU6JRWK=
BT-474	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\jNWlEPTB;MD6wNVk1OyEQvF2=	NFrXSIJUSU6JRWK=
OAW-28	NH\qeFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX74WIFPUUN3ME2wMlAyQTV4IN88US=>	NXrVRmVjW0GQR1XS
ES6	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTBwMEKwNFgh\|ryP	MmfNV2FPT0WU
PC-3	NGe5NlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWnIeGY1UUN3ME2wMlAzODN4IN88US=>	NFr5eoFUSU6JRWK=
COR-L88	MlK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPhXlVKSzVyPUCuNFIxPTRizszN	NFvXSpVUSU6JRWK=
D-392MG	Mn;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PSNmlEPTB;MD6wNlA3QCEQvF2=	Ml3EV2FPT0WU
LB2518-MEL	NXXE[INZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3W3bWlEPTB;MD6wNlE3OSEQvF2=	M1XJO3NCVkeHUh?=
LoVo	MoHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWHCc4hxUUN3ME2wMlAzOTd{IN88US=>	M3rkPHNCVkeHUh?=
HCC1954	NE[1cVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTBwMEKxPVIh\|ryP	NEfvfG9USU6JRWK=
COLO-792	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX;JR\|UxRTBwMEKxPVYh\|ryP	MXPTRW5ITVJ?
KLE	NUexSVdNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVqyN45KUUN3ME2wMlAzOzJ\|IN88US=>	NUD2XpZCW0GQR1XS
MDA-MB-157	NXfvOZd3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTBwMEKzOFkh\|ryP	NGCzS4pUSU6JRWK=
PANC-08-13	NUO4WYJTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWP5[ZZPUUN3ME2wMlAzPDZ3IN88US=>	NH;BOJBUSU6JRWK=
NCI-H727	Ml3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRTBwMEK0O\|Qh\|ryP	M374d3NCVkeHUh?=
NCI-H1155	MkXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTBwMEK0O\|ch\|ryP	NVPsPYJRW0GQR1XS
GCIY	M3;QOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF34OFVKSzVyPUCuNFI2ODJizszN	M4HYOXNCVkeHUh?=
MKN1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{P5S2lEPTB;MD6wNlU4PiEQvF2=	M{TvUnNCVkeHUh?=
NCI-H1092	NWOxRnVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHTOTZJKSzVyPUCuNFI3PTRizszN	M4\2RnNCVkeHUh?=
RMG-I	MkDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEXWVGFKSzVyPUCuNFI4KM7:TR?=	NH\BTY9USU6JRWK=
NB12	NFP3S\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHWxXndKSzVyPUCuNFI4OiEQvF2=	MUjTRW5ITVJ?
RCM-1	NI\sVXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4LxXWlEPTB;MD6wNlgyQSEQvF2=	NYrQVHdNW0GQR1XS
C3A	MlLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGLafpVKSzVyPUCuNFI5OjJizszN	Mkf2V2FPT0WU
NCI-H747	M4PwbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{HU[mlEPTB;MD6wNlg{PyEQvF2=	NYTSVoU4W0GQR1XS
LB771-HNC	Mly1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmTiTWM2OD1yLkCyPFM4KM7:TR?=	MlzwV2FPT0WU
EW-13	NXu5[lZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33GbmlEPTB;MD6wNlkxPCEQvF2=	M2nCdXNCVkeHUh?=
CAL-72	M1XKOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLvTWM2OD1yLkCyPVE5KM7:TR?=	MYfTRW5ITVJ?
HH	Mlu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVnBZpZUUUN3ME2wMlAzQTl6IN88US=>	NXH4Rm1EW0GQR1XS
UACC-257	M{T5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWXRWGNsUUN3ME2wMlA{ODNizszN	MYXTRW5ITVJ?
OAW-42	NHPTPWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\SblBKSzVyPUCuNFMxOyEQvF2=	NGPSUnRUSU6JRWK=
CAPAN-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3zb45LUUN3ME2wMlA{ODV{IN88US=>	NYLjRpJEW0GQR1XS
SNU-C2B	M4qybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3P1TGlEPTB;MD6wN\|A3OyEQvF2=	M2rz[XNCVkeHUh?=
NKM-1	MkTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTBwMEOxOlkh\|ryP	NYHr[VZQW0GQR1XS
GR-ST	M{HITmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLoZ5VKSzVyPUCuNFMyQDVizszN	MXrTRW5ITVJ?
SW1463	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HMV2lEPTB;MD6wN\|M{PyEQvF2=	M1zLN3NCVkeHUh?=
MEL-HO	NHTmVIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4ixWGlEPTB;MD6wN\|QzOSEQvF2=	NEnxNJFUSU6JRWK=
NCI-H2342	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV\JR\|UxRTBwMEO2N\|Mh\|ryP	Ml3aV2FPT0WU
ACHN	NGfvdG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTBwMEO3NUDPxE1?	NHPzO2xUSU6JRWK=
RH-18	NGH6fW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXG0WW5PUUN3ME2wMlA{PzZ\|IN88US=>	M4nHPHNCVkeHUh?=
HCC2218	M2jmcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIDTd5JKSzVyPUCuNFM4QSEQvF2=	MlrGV2FPT0WU
OS-RC-2	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnG4TWM2OD1yLkCzPFY6KM7:TR?=	NITT[HdUSU6JRWK=
KP-N-YN	M1HMdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnMT\|RKSzVyPUCuNFM5PzZizszN	M4DJTXNCVkeHUh?=
COLO-668	NGTnXplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTBwMEO4PFch\|ryP	Mm[yV2FPT0WU
LU-65	MmPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTBwMEO5NFQh\|ryP	M1XFOXNCVkeHUh?=
NB6	NGTPcJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTYRVBnUUN3ME2wMlA{QTV{IN88US=>	MWnTRW5ITVJ?
HT	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mon3TWM2OD1yLkC0NFA4KM7:TR?=	NUm2OYRtW0GQR1XS
COLO-684	MmWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlT5TWM2OD1yLkC0NFk2KM7:TR?=	NX\Ld3FyW0GQR1XS
NCI-H1693	NYm1ZXNVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFjpe5RKSzVyPUCuNFQ{ODVizszN	NIricJpUSU6JRWK=
LAN-6	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHvU3FCUUN3ME2wMlA1OzN3IN88US=>	Ml\0V2FPT0WU
MDA-MB-175-VII	M1\vN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{DXSGlEPTB;MD6wOFQyPyEQvF2=	MVLTRW5ITVJ?
KMOE-2	M4TYRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;pTWM2OD1yLkC0OFY6KM7:TR?=	MY\TRW5ITVJ?
DMS-79	MnPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2iwOGlEPTB;MD6wOFU4QSEQvF2=	MYrTRW5ITVJ?
MHH-NB-11	M1i0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTBwMES2NVQh\|ryP	NWq4U2w6W0GQR1XS
NCI-H69	NITXXphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGftbWhKSzVyPUCuNFQ5PDlizszN	NFPFRndUSU6JRWK=
KE-37	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXu3blNiUUN3ME2wMlA2ODFizszN	NV\2RllLW0GQR1XS
Ramos-2G6-4C10	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\wTWM2OD1yLkC1NFY4KM7:TR?=	NF7ZdWRUSU6JRWK=
NCI-H1793	NE\WfYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTBwMEWwPVMh\|ryP	M1TzO3NCVkeHUh?=
HT-1376	M2juZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV3JR\|UxRTBwMEWxPFYh\|ryP	NVuyNIVbW0GQR1XS
EKVX	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mor4TWM2OD1yLkC1N\|g1KM7:TR?=	NFrvPHBUSU6JRWK=
Capan-2	NFf5Ro9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLHTWM2OD1yLkC1N\|k3KM7:TR?=	MluxV2FPT0WU
DoTc2-4510	M4LMTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M33iNWlEPTB;MD6wOVQ1PiEQvF2=	NHPONVlUSU6JRWK=
UACC-893	M33ReWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvRTmlCUUN3ME2wMlA2PDZ{IN88US=>	NWqy[G1OW0GQR1XS
SK-MEL-3	MmfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTBwMEW3PFgh\|ryP	MnrLV2FPT0WU
SK-MEL-1	M4Hw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTBwMEW4JO69VQ>?	M{GwbXNCVkeHUh?=
SW948	M2flTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3PrNGlEPTB;MD6wOVk6PiEQvF2=	MUjTRW5ITVJ?
P30-OHK	M2jXVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3TWemlEPTB;MD6wOlE3PyEQvF2=	NFvQUWZUSU6JRWK=
NH-12	NV7sXpZNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\aTWM2OD1yLkC2NlQ1KM7:TR?=	M3LMdHNCVkeHUh?=
KU-19-19	NHixXGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnHyTWM2OD1yLkC2N\|YyKM7:TR?=	MnT1V2FPT0WU
A431	NUO0U2ZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTBwME[zO\|Qh\|ryP	MlHkV2FPT0WU
NCI-H2405	NHHZVnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TxZmlEPTB;MD6wOlM5OyEQvF2=	M2\MWXNCVkeHUh?=
KARPAS-299	MnrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NITmdYJKSzVyPUCuNFY2QDJizszN	M3zBNnNCVkeHUh?=
BALL-1	M1frOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLuU5BKSzVyPUCuNFY3PzRizszN	NUHlepljW0GQR1XS
KURAMOCHI	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\3PVhKSzVyPUCuNFcxPzNizszN	NFzYRplUSU6JRWK=
LS-1034	MlvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlv0TWM2OD1yLkC3N\|Y6KM7:TR?=	NEPEcndUSU6JRWK=
MFE-280	NIHxbGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Moq2TWM2OD1yLkC3OVM3KM7:TR?=	NHPqO49USU6JRWK=
HOP-62	NHHkRlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTBwMEe2O\|Yh\|ryP	NIPMWWxUSU6JRWK=
KG-1	NU\RSG1lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTBwMEe3PFch\|ryP	NFfrPG5USU6JRWK=
CW-2	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml3yTWM2OD1yLkC3PFMzKM7:TR?=	M4nS[HNCVkeHUh?=
SW837	MkW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17abmlEPTB;MD6wPFM1OiEQvF2=	NVS0c4tsW0GQR1XS
MFH-ino	NEjQNVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M13ZTGlEPTB;MD6wPFUxOSEQvF2=	MkPUV2FPT0WU
HCC1419	M1;5OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFmwdFVKSzVyPUCuNFg6QDdizszN	NYT2S\|ZsW0GQR1XS
HMV-II	MnrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHe5O3hKSzVyPUCuNFkxOSEQvF2=	MWXTRW5ITVJ?
BEN	NF:4WVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXv2Z4NMUUN3ME2wMlA6Ozh3IN88US=>	MofEV2FPT0WU
SK-N-FI	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTOZldjUUN3ME2wMlA6PTV4IN88US=>	NHvnZZZUSU6JRWK=
JVM-2	NGmwbXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3O5SWlEPTB;MD6wPVcyPiEQvF2=	NGrOcnpUSU6JRWK=
CAL-54	Mn6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fGbmlEPTB;MD6xNFA1KM7:TR?=	M{HTcnNCVkeHUh?=
T84	MkDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37CbWlEPTB;MD6xNFk2OiEQvF2=	NVvxPFA2W0GQR1XS
SHP-77	MkfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPVZoZKSzVyPUCuNVE3PDFizszN	M3PxR3NCVkeHUh?=
G-361	M1XHNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIT2OXNKSzVyPUCuNVI{OjRizszN	M2HxVHNCVkeHUh?=
Calu-3	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zWNmlEPTB;MD6xN\|gyPiEQvF2=	M{\6SXNCVkeHUh?=
HCC1937	MnvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX:w[o9RUUN3ME2wMlE1QTN5IN88US=>	NFSzVG5USU6JRWK=
KM-H2	Mle5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWnmblF6UUN3ME2wMlE2ODFizszN	MULTRW5ITVJ?
769-P	NGHwUlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnriTWM2OD1yLkG1PFQ{KM7:TR?=	MnHuV2FPT0WU
NCI-H1304	NVXXR4RoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTBwMU[wOlEh\|ryP	MlrnV2FPT0WU
D-542MG	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXnb5FKSzVyPUCuNVYzPzhizszN	MlHwV2FPT0WU
ATN-1	MnHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoXoTWM2OD1yLkG3OFQyKM7:TR?=	MWTTRW5ITVJ?
NCI-H2029	NV7TeVJIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPU[29NUUN3ME2wMlIxOjR\|IN88US=>	MXfTRW5ITVJ?
ZR-75-30	M3\kS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWO5Xo5sUUN3ME2wMlIxPjR\|IN88US=>	NGrVb5FUSU6JRWK=
SW1116	M3;RTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1frRWlEPTB;MD6yNVEyPyEQvF2=	MVjTRW5ITVJ?
CCRF-CEM	M{nDc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HQOGlEPTB;MD6yO\|YyPCEQvF2=	NWDQSVhVW0GQR1XS
LU-135	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUX4ZmdGUUN3ME2wMlI4PzN7IN88US=>	NFP5fI9USU6JRWK=
MC116	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{fJS2lEPTB;MD6yPFMxQSEQvF2=	MV7TRW5ITVJ?
LS-513	NE\We5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTBwMki3O\|Mh\|ryP	MlfBV2FPT0WU
NCI-H630	MmTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTBwMkmzO\|Yh\|ryP	NWr1V3p3W0GQR1XS
L-428	M4nLVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlnyTWM2OD1yLkK5PFg{KM7:TR?=	MmXXV2FPT0WU
UM-UC-3	NIDMeWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mli1TWM2OD1yLkOxNlkyKM7:TR?=	Ml;2V2FPT0WU
NCI-H1838	NXK2SpB{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlmxTWM2OD1yLkOxO\|g1KM7:TR?=	MXLTRW5ITVJ?
HEL	NV\mWmVnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTBwM{KyOEDPxE1?	NUXiRWNWW0GQR1XS
OCI-AML2	NIe2cnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTBwM{KyPVgh\|ryP	NILj[HdUSU6JRWK=
A3-KAW	M3TqdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnnWTWM2OD1yLkOzOFc4KM7:TR?=	M2jDXHNCVkeHUh?=
IGROV-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;nW3hZUUN3ME2wMlM{PzV3IN88US=>	MWDTRW5ITVJ?
Mo-T	NWCwTJRsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2nQfWlEPTB;MD6zN\|g2OyEQvF2=	NGPJc5dUSU6JRWK=
HDLM-2	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7PSGVrUUN3ME2wMlM{QSEQvF2=	NH;pRoVUSU6JRWK=
HCC1569	NWDqWXluT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFyybHNKSzVyPUCuN\|Q{ODlizszN	MWXTRW5ITVJ?
COLO-678	NHvYc3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHjKe3JKSzVyPUCuN\|cxODJizszN	MYTTRW5ITVJ?
COR-L105	NV7ido45T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTBwM{e5N{DPxE1?	M3\JbHNCVkeHUh?=
SK-MEL-24	M3zLTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTBwM{izPFIh\|ryP	MX;TRW5ITVJ?
COLO-320-HSR	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTBwNEO5O\|Yh\|ryP	NWfnZo5VW0GQR1XS
C8166	NYHLcoZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUjJR\|UxRTBwNEmwNlMh\|ryP	M3\EUnNCVkeHUh?=
COLO-679	NVLpV2htT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTBwNkKxO\|Ih\|ryP	NHf6eWFUSU6JRWK=
TE-12	NHnsT2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkXoTWM2OD1yLk[1N\|k1KM7:TR?=	NH\oSIpUSU6JRWK=
HAL-01	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoryTWM2OD1yLk[2NlIh\|ryP	NVTYfGpiW0GQR1XS
H-EMC-SS	M1H0V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXLaZ3lyUUN3ME2wMlcxPTR4IN88US=>	Mkm1V2FPT0WU
SNU-449	NUjaRWFWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnTMTWM2OD1yLkeyO\|Q5KM7:TR?=	MoKwV2FPT0WU
C32	MmD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTBwN{SxNVIh\|ryP	MVnTRW5ITVJ?
K-562	M2XlR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTBwN{ewNlQh\|ryP	MYTTRW5ITVJ?
DJM-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTBwN{i3PFEh\|ryP	Mn2xV2FPT0WU
RCC10RGB	NVfMbnVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTBwN{mxPFMh\|ryP	MkXjV2FPT0WU
CAL-85-1	NGrMWIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\C[mVKSzVyPUCuPVA4KM7:TR?=	MlriV2FPT0WU
NY	MoPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2rIPWlEPTB;MD65N\|M2OiEQvF2=	MmXKV2FPT0WU
NCI-H1993	NHz0TIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1HX[2lEPTB;MT6xPVI5QSEQvF2=	Mn7mV2FPT0WU
SK-OV-3	NF75PWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfJbJlKSzVyPUGuNlIxQDlizszN	NWrZZmYxW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	PIM1; PubMed: 18426800 J Biol Chem Cells were treated with 100 nm docetaxel for the indicated times. PIM1 and β-ACTIN proteins were analyzed by immunoblot analysis. One of three similar blots is shown. Ratio, ratio of PIM1/β-ACTIN from pooled densitometry data from three separate experimen䲧疝Ỵ疞㧀疜膉痘 瘿뾠ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ⟸෕䐺痖暼瘿⟸෕ᾰƌ cyclin B; PubMed: 18426800 J Biol Chem Immunoblot analysis of cyclin B1 and PIM1 expression after docetaxel 10 nm (left) or 100 nm (right) treatment at various time points. pSTAT3 / STAT3 ; PubMed: 18426800 J Biol Chem Immunoblots of RWPE-2 cells treated with 100 nm docetaxel for the indicated time. p-p53 / p53; PubMed: 22996738 Prostate C4-2 cells were treated with 5 nM docetaxel, the whole cell lysates were collected at different time points and subjected to Western blot.	18426800 22996738
Immunofluorescence	α-tubulin; PubMed: 27177833 Exp Cell Res Noscapine has no effect on gross microtubule polymerization state but noscapine pre-sensitization followed by docetaxel treatment stabilizes microtubules, hence inhibits cell proliferation. TNBC cells were treated with noscapine (4 µM) or docetaxel (0.4 µ䲧疝Ỵ疞㧀疜膉痘 瘿⟸෕ᾰƌ෕Ð 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෕Ð鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ뾠Ղ䐺痖暼瘿뾠Ղᾰƌ 뾠ՂÐ㺣痖뾠Ղ𢡄뾤Ղ䀷痗뾤Ղ౴뾤Ղ㵶痗뾤Ղ뺖᎒泌Itemｾ᎒Count﫨呂뿔Ղ猴፲뾤Ղ፲씢痗猸፲髸莤䥷堙᎒ｾ᎒�堞ﻮ᎒፲露𢡄堚Ҕ齃礤v�堞ﻮ᎒猢Wｾ᎒䨼Ą鹿齃殺獸W戀醙 cleaved PARP / cleaved caspase-3; PubMed: 21087597 Biochem Pharmacol Immunofluorescence images of PC-3 cells treated with the docetaxel and EM011 schedule treatment. Cells were pretreated with docetaxel for 12 h before addition of EM011 and were fixed at 48 h post docetaxel treatment compared to treatment with EM011 (10 μM䲧疝Ỵ疞㧀疜膉痘 瘿⟸෕ᾰƌ෕Ð 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෕Ð鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ�෋䐺痖暼瘿�෋ᾰƌ �෋à Acetylated tubulin ; PubMed: 18426800 J Biol Chem Immunofluorescence of acetylated tubulin in cells treated with DMSO, 30 nM laulimalide and 30 nM docetaxel for 2.5 h. Tubulin shown in green and DAPI in blue, and the white arrow indicates microtubule bundling. Scale bar represents 10 μm. SQSTM1 / LAMP1; PubMed: 29795139 Cell Death Dis AGS cells were treated with docetaxel (10 nM) for 12 h. After immunostaining with SQSTM1 (Alexa Fluor 488, green) and LAMP1 (Alexa Fluor 594, red), cells were examined by fluorescence microscopy (scale bar 20 μm). The colocalization of SQSTM1and LAMP1 was䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ	27177833 21087597 18426800 29795139
Growth inhibition assay	Cell viability ; PubMed: 22996738 Prostate Docetaxel inhibits the growth of LNCaP, C4-2, DU145, and PC3 prostate cancer cells. Cells were plated in 12-well plates and treated with different concentrations of docetaxel. The cell number was counted after 24 hr.	22996738

In vivo

Docetaxel (33 mg/kg/dose, given i.v. every 4 days for 3 injections) results in a tumor growth delay of 19.3 days in M2OL2 colon xenografts. Docetaxel also shows great antitumor activities in MX-1, SK-MEL-2, LX-1 and OVCAR-3 xenografts. Docetaxel inhibits the angiogenic response to fibroblast growth factor 2 with IC 50 of 5.4 mg/kg when injected twice weekly over a 14-day period, and angiogenesis is completely blocked in mice that receives 10 mg/kg Docetaxel. Docetaxel has selectivity for endothelial cell migration and/or microvessel formation because infiltration of inflammatory cells into the Matrigel plug is much less sensitive to inhibition by Docetaxel. ^[7]

Protocol

Cell Research:^[5]

- Collapse

Cell lines: Human gastric cancer cell lines MKN-28
Concentrations: 6 nM
Incubation Time: 3 days
Method: 2000 cells in 180 μL of medium are seeded in a 96-well plate, and 20 μL of drug solution is simultaneously added in triplicate to each well. The plate is incubated for 3 days at 37°C in a humidified atmosphere of 5% CO₂. On day 3, 25 μL of MTT reagent is added to each well. After 4 h of incubation, the medium is removed by aspiration. 0.2 mL of dimethylsulphoxide (DMSO) is added to each well and thoroughly mixed by using a mechanical plate mixer to dissolve the resulting MTT-formazan crystals. Absorbance at 540 nm (OD) is measured by a reader.
(Only for Reference)

Animal Research:^[6]

- Collapse

Animal Models: Human colon carcinomas xenografts CX-1
Dosages: 33 mg/kg
Administration: i.v. every 4 days for 3 injections
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	100 mg/mL (123.78 mM)
	Water	Insoluble
	Ethanol	''53 mg/mL warmed
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Docetaxel SDF

Molecular Weight	807.88
Formula	C₄₃H₅₃NO₁₄
CAS No.	114977-28-5
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	RP56976, NSC 628503
Smiles	CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04396535	Not yet recruiting	Drug: Bintrafusp Alfa\|Drug: Docetaxel	Advanced Lung Non-Small Cell Carcinoma\|Stage III Lung Cancer AJCC v8\|Stage IIIA Lung Cancer AJCC v8\|Stage IIIB Lung Cancer AJCC v8\|Stage IIIC Lung Cancer AJCC v8\|Stage IV Lung Cancer AJCC v8\|Stage IVA Lung Cancer AJCC v8\|Stage IVB Lung Cancer AJCC v8	Mayo Clinic\|National Cancer Institute (NCI)	December 1 2020	Phase 2
NCT04471675	Not yet recruiting	Drug: Albumin-bound docetaxel	Advanced Solid Tumors	CSPC ZhongQi Pharmaceutical Technology Co. Ltd.	November 15 2020	Phase 1
NCT04467801	Not yet recruiting	Drug: Ipatasertib	NSCLC Stage IV\|NSCLC Stage IIIB	University of Kansas Medical Center\|University of Iowa\|University of Kentucky	August 2020	Phase 2
NCT04364620	Not yet recruiting	Drug: AB-16B5\|Drug: Docetaxel	NSCLC Stage IV	Alethia Biotherapeutics	August 2020	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

TAI-1 ^New

TAI-1 is a potent and specific Hec1 inhibitor, which disrupts Hec1-Nek2 protein interaction.
Docetaxel Trihydrate ^New

Docetaxel (RP56976, NSC 628503), an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.
Combretastatin A4 ^New

Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with K_d of 0.4 μM.Phase 3.
Paclitaxel

Paclitaxel (NSC 125973, PTX, Taxol, Onxal) is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.
Vincristine sulfate

Vincristine sulfate (Leurocristine) is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay. Vincristine sulfate induces apoptosis.
Nocodazole

Nocodazole is a rapidly-reversible inhibitor of microtubule polymerization, also inhibits Abl, Abl(E255K) and Abl(T315I) with IC50 of 0.21 μM, 0.53 μM and 0.64 μM in cell-free assays, respectively. Nocodazole induces apoptosis.
Vinorelbine Tartrate

Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin. Vinorelbine Tartrate exhibits anti-tumor activities via inducing the mitotic apoptosis, autophagy and inflammation.
Cabazitaxel

Cabazitaxel (RPR-116258A, XRP6258, TXD 258) is a semi-synthetic derivative of a natural taxoid that kills cancer cells by inhibiting cell division and growth. Cabazitaxel exerts its effects by inhibiting microtubule growth and assembly, processes that are essential for cells to divide. Cabazitaxel induces autophagy via the PI3K/Akt/mTOR pathway.

Features:A semi-synthetic derivative of a natural taxoid.
Patupilone (Epothilone B)

Patupilone (EPO906, Epothilone B) is a paclitaxel-like microtubule-stabilizing agent with EC_0.01 of 1.8 μM. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Docetaxel